OS stratified by the different “eras” of treatment
| . | n . | OS from the first treatment . | P value . | |
|---|---|---|---|---|
| % at 5 years . | % at 10 years . | |||
| Prerituximab era (1987-2009) | .58 | |||
| Controls | 14 | 92.9 | 85.7 | |
| Cases | 11 | 90.9 | 90.9 | |
| Preinhibitors era (2010-2015) | .89 | |||
| Controls | 28 | 92.9 | 80.9 | |
| Cases | 15 | 86.7 | 78.0 | |
| Inhibitors era (2016-2024) | .98 | |||
| Controls | 94 | 86.4 | n.a. | |
| Cases | 62 | 84.6 | n.a. | |
| . | n . | OS from the first treatment . | P value . | |
|---|---|---|---|---|
| % at 5 years . | % at 10 years . | |||
| Prerituximab era (1987-2009) | .58 | |||
| Controls | 14 | 92.9 | 85.7 | |
| Cases | 11 | 90.9 | 90.9 | |
| Preinhibitors era (2010-2015) | .89 | |||
| Controls | 28 | 92.9 | 80.9 | |
| Cases | 15 | 86.7 | 78.0 | |
| Inhibitors era (2016-2024) | .98 | |||
| Controls | 94 | 86.4 | n.a. | |
| Cases | 62 | 84.6 | n.a. | |
n.a., not available.